Evidence map›Paper›PMID 37312845›Full record

ArticleACS medicinal chemistry letters2023

Antimicrobial Peptides Incorporating Halogenated Marine-Derived Amino Acid Substituents.

Alexander J Craig, Yuri Ermolovich, Alan Cameron, Agnes Rodler, Helen Wang, Jeffrey A Hawkes, Madlen Hubert, Fredrik Björkling, Natalia Molchanova, Margaret A Brimble and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alexander J CraigDrug Design and Discovery, Department of Medicinal Chemistry, Biomedical Centre, Uppsala University, 75123 Uppsala, Sweden.
Yuri ErmolovichDepartment of Drug Design and Pharmacology, University of Copenhagen, DK-2100 Copenhagen, Denmark.ORCID https://orcid.org/0000-0003-3498-1890
Alan CameronSchool of Chemical Sciences, University of Auckland, 23 Symonds Street, Auckland 1010, New Zealand.
Agnes RodlerDepartment of Pharmacy, Biomedical Centre, Uppsala University, 75123 Uppsala, Sweden.
Helen WangDepartment of Medical Biochemistry and Microbiology, Biomedical Centre, Uppsala University, 75123 Uppsala, Sweden.
Jeffrey A HawkesAnalytical Chemistry, Department of Chemistry, Biomedical Centre, Uppsala University, 75123 Uppsala, Sweden.ORCID https://orcid.org/0000-0003-0664-2242
Madlen HubertDepartment of Pharmacy, Biomedical Centre, Uppsala University, 75123 Uppsala, Sweden.
Fredrik BjörklingDepartment of Drug Design and Pharmacology, University of Copenhagen, DK-2100 Copenhagen, Denmark.ORCID https://orcid.org/0000-0001-7018-8334
Natalia MolchanovaThe Molecular Foundry, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States.
Margaret A BrimbleSchool of Chemical Sciences, University of Auckland, 23 Symonds Street, Auckland 1010, New Zealand.ORCID https://orcid.org/0000-0002-7086-4096
Lindon W K MoodieDrug Design and Discovery, Department of Medicinal Chemistry, Biomedical Centre, Uppsala University, 75123 Uppsala, Sweden.ORCID https://orcid.org/0000-0002-9500-4535
Johan SvensonCawthron Institute, 98 Halifax Street East, Nelson 7010, New Zealand.ORCID https://orcid.org/0000-0002-4729-9359

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small synthetic mimics of cationic antimicrobial peptides represent a promising class of compounds with leads in clinical development for the treatment of persistent microbial infections. The activity and selectivity of these compounds rely on a balance between hydrophobic and cationic components, and here, we explore the activity of 19 linear cationic tripeptides against five different pathogenic bacteria and fungi, including clinical isolates. The compounds incorporated modified hydrophobic amino acids inspired by motifs often found in bioactive marine secondary metabolites in combination with different cationic residues to probe the possibility of generating active compounds with improved safety profiles. Several of the compounds displayed high activity (low μM concentrations), comparable with the positive controls AMC-109, amoxicillin, and amphotericin B. A higher activity was observed against the fungal strains, and a low

Identifiers

PMID37312845
PMCPMC10258904

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.